CBD Life Sciences Inc. (CBDL) Announces Groundbreaking 100MG Full Spectrum CBD Gummy Geared Toward Mental Health & Focus
With the global CBD market expected to exceed $60 billion by 2030, and the mental wellness industry surging past $500 billion, CBD Life Sciences Inc. (OTC:CBDL) is strategically positioning itself at the center of two of the fastest-growing markets in modern health.
SCOTTSDALE, AZ / ACCESS Newswire / April 22, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL) a leader in cannabinoid-driven health innovation - proudly announces the launch of its most anticipated product to date: a high-dosage 100MG Full Spectrum CBD Gummy, meticulously formulated to support mental health, daily focus, and emotional well-being.
Available in mouth-watering Crisp Green Apple and Wild Blueberry flavors, this isn't your average CBD gummy. It's a next-generation wellness tool - designed not only to relax the body but to sharpen the mind. Crafted with full-spectrum cannabinoids, these gummies are being positioned as a natural ally in the pursuit of mental clarity, balance, and daily productivity.
'Mental health isn't a trend - it's a global crisis. And people are tired of band-aid solutions,' said Lisa Nelson, President & CEO of CBD Life Sciences Inc. 'This product was built to empower people who want to feel better and function better - without the side effects of traditional pharmaceuticals. It's a powerful, natural alternative that speaks directly to the stress, anxiety, and attention struggles millions face every day.'
Lab tested and verified with Certificates of Analysis (COAs), this 100MG gummy represents the company's deepest push yet into the lucrative mental wellness category. Unlike many low-dose competitors, CBDL's bold formulation is made for people who need real results - entrepreneurs, creatives, students, parents, and professionals looking to stay in control of their mood and mindset.
Early conversations with several wellness clinics and mental health centers are already in progress, exploring how this high-potency gummy could be integrated into patient routines. While no formal agreements have been made, the demand is clear: health professionals are actively seeking natural, high-quality, lab-verified CBD options to complement modern mental wellness protocols.
CBDL is rapidly building a portfolio that taps into high-value niches: from pain relief and nano-enhanced beverages to functional CBD coffee creamers and now, this cutting-edge product for mental clarity. The company's ability to stay ahead of trends and deliver results has attracted attention from both investors and the wellness industry.
'We're not trying to follow the market - we're reshaping it,' Nelson added. 'With this launch, we're doubling down on our belief that the future of wellness lies in functional, focused, and effective cannabinoid products.'
This release is a bold statement to shareholders and the industry: CBD Life Sciences Inc. is serious about mental health. The company's momentum continues to build, and with this new launch, they're inviting wellness professionals, retail buyers, and everyday users to experience the next level of what CBD can offer.
The 100MG Mental Health Gummies are available now, with full lab reports and wholesale interest forms available on the company's website.
For product information, COAs, or wholesale inquiries, please visit www.thecbdvault.com.
About CBD Life Sciences Inc.
CBD Life Sciences Inc. (CBDL) is a leading innovator in the wellness and alternative health sector, specializing in high-quality CBD and functional mushroom products designed to enhance well-being. With a commitment to scientific research and consumer safety, CBDL continues to push the boundaries of holistic health solutions, creating opportunities for exponential growth in a rapidly evolving market.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: [email protected]
Stay Connected & Be the First to Try Our New Functional Mushroom Products!
Mushroom Madness Instagram: https://www.instagram.com/mushroom.madnessaz
Mushroom Madness Website: https://www.mushroommadness.shop
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
[email protected]
4802091720
SOURCE: CBD Life Sciences, Inc.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Proposed bill would allow Pennsylvania students to take mental health days
PENNSYLVANIA (WTAJ) — A representative announced plans to model new legislation after a current Utah law that allows students to take mental health days. Representative Napoleon Nelson (D-Montgomery County) called mental health a 'significant issue' among students and youth. Adding that in a 2023 report, 98,000 students have depression and over half had not received care for their mental health. 'Additionally, high school students with depression are more than two times more likely to drop out than their peers, and suicide is the second leading cause of death among adolescents,' Nelson wrote. 'Fanta's Law' aims to require Pennsylvania police firearms training courses The proposed legislation would be modeled after a current law in Utah. The bill would allow students to take excused absences to recover from mental health issues, while not creating additional personal or sick days. An additional part of the legislation would require a staff member to talk to a student who has taken two or more mental health days. In a memo to lawmakers, the additional part of the legislation would make it so that students can be connected to mental health support. 'Student mental health is just as important as physical health, and normalizing support for students with mental health issues has increased in the last several years. Teen mental health has been recognized as a crisis, and it is important for the Commonwealth to take charge in protecting the well-being of its citizens,' Nelson wrote. Nelson argues that these are the benefits of the proposed legislation: Normalizes mental health support and encourages students to take care of their mental health Provides schools with additional insight Would allow schools to connect students with essential supports rather than simply punishing them The full memo to lawmakers can be read here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Indianapolis Star
2 days ago
- Indianapolis Star
Moderna Announces Update on Investigational Pandemic Influenza Program
Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype. The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines. 'While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.' The Phase 1/2 study evaluated a two-dose regimen of Moderna's investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response. At baseline, pre-existing immunity was minimal, with only 2.1% of participants showing hemagglutination inhibition (HAI) antibody titers ≥1:40, an HAI titer considered to correlate with protection. At Day 43, three weeks after the second vaccination, 97.8% of participants achieved titers ≥1:40 with a 44.5-fold increase of titers from baseline. The investigational vaccine was generally well-tolerated, with no dose-limiting tolerability concerns observed. Most solicited adverse reactions were Grade 1 or 2 and did not increase significantly with number of doses or between first and second doses. Further data is expected to be submitted for presentation at an upcoming scientific meeting. Moderna will explore alternatives for late-stage development and manufacturing of the H5 program consistent with the Company's strategic commitment to pandemic preparedness. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the clinical development of mRNA-1018, the safety and immunogenicity data from the Phase 1/2 study; the cancellation of the development contract for Moderna's pandemic flu program by the U.S. Department of Health and Human Services; and the exploration of alternative paths for development of the vaccine program. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire
Yahoo
2 days ago
- Yahoo
How Will Quantum Technologies Transform the $9.8 Trillion Global Healthcare Sector?
A recent publication by quantum researcher Ali Karakuş draws the attention of the medical industry. BERLIN, DE / / June 5, 2025 / Quantum researcher Ali Karakuş has published a groundbreaking scientific paper that challenges the foundations of modern medicine and proposes a bold new perspective on health. The study introduces a next-generation medical model based on quantum sensors, ethical artificial intelligence, and resonance-based diagnostics-aiming to redefine our understanding of illness and healing. Global healthcare expenditures now exceed $9.8 trillion per year. Yet, despite this enormous financial investment, chronic illnesses, mental health disorders, and stress-related conditions are on the rise. According to Karakuş, the problem is not technological scarcity but the loss of harmonic alignment between humans, nature, and their own bodies. "We measure numbers but fail to listen to frequencies," says Karakuş. "We treat symptoms, yet overlook resonance breakdowns. The body must no longer be viewed as matter alone, but as a field of waves and energy." From Symptom Suppression to Resonance Restoration At the heart of the study is a quantum-sensor-based device in development that analyzes brainwaves, heart rate variability (HRV), vagus nerve activity, microbiome signals, and ethical resonance scores. All of this data is then processed by an ethical AI engine called Zulficore, producing a holistic and personalized feedback loop. A New Question for Medicine: "What's wrong?" or "What's out of tune?" The system designed by SlientWing integrates multiple disciplines including quantum biology, neuroscience, biomimetics, ecological AI, and ethics-based algorithms. The core question is shifting: Not "What disease do you have?" But "What frequency is disturbed? Which resonance with nature is lost?" Launch Timeline The beta version of the SlientWing device is expected to be field-tested by late 2026, with full-scale production and market launch scheduled for 2027. Manufacturing will be centered in Berlin and Thrace. Contact Information Ali Karakus Founderali@ SOURCE: Neuroscience & Quantum Researcher Ali Karakus View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
